Rapid Characterization of Paucibacillary TB Along Tex/Mex Border
Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, HOUSTON · Jan 11, 2007
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Global challenges to tuberculosis (TB) control are multidrug resistance TB (MDR-TB) and the increased susceptibility of populations such as elderly, those with HIV infection, type 2 diabetes and other immunosuppressive chronic diseases. The first primary study objective is to examine the potential of the investigators' new DNA extraction/qPCR protocol as a non-invasive tool to study pathogenesis in a range of paucibacillary specimens. The investigators will evaluate their DNA extraction/qPCR assays prospectively in specimens from patients with paucibacillary TB, including extra-pulmonary TB...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- For Cases and Controls:
- • Informed consent obtained and signed
- • Older than 18 years of age, up to 85 years of age
- Unique to Cases:
- • -Suspicion of smear-negative pulmonary tuberculosis, lymphatic tuberculosis or pleural tuberculosis
- Unique to Controls:
- • Initial suspicion of tuberculosis (as described under cases) but diagnosis eventually ruled out through further testing
- • Patient with another pathology where specimen similar to that collected for the cases is also obtained, and leftover material is available for this study; example- lymph node biopsy from a patient with cancer
- Exclusion Criteria:
- • Patient having received more than 14 days of anti-mycobacterial treatment
- • Less than 18 years old
- • Prisoner or jail inmate
About The University Of Texas Health Science Center, Houston
The University of Texas Health Science Center at Houston (UTHealth) is a leading academic institution dedicated to advancing health through education, research, and clinical practice. As a prominent sponsor of clinical trials, UTHealth leverages its extensive resources and expertise in biomedical research to facilitate innovative studies aimed at improving patient outcomes. The institution is committed to fostering a collaborative environment that promotes scientific discovery and the translation of research findings into effective healthcare solutions, all while adhering to the highest ethical standards and regulatory guidelines. With a multidisciplinary approach, UTHealth plays a critical role in addressing complex health challenges and enhancing the quality of life in diverse communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brownsville, Texas, United States
Medellin, , Colombia
Matamoros, , Mexico
Patients applied
Trial Officials
Blanca Restrepo, PhD
Principal Investigator
UT Health Science Center at Houston -School of Public Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials